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An estimated 240 million chronic hepatitis B virus 
(HBV) infections have been reported worldwide 
despite the availability of an effective vaccine.[1] South 
Africa (SA) introduced the HBV vaccine into the 
national Expanded Programme on Immunisation 
(EPI) in 1995.[2] The vaccine is given to infants at 6, 10 and 14 
weeks of age.[2] Adults are not routinely immunised against HBV, so 
women born before 1995 would have no vaccine immunity against 
HBV. Between 1995 and 1999, 31% of mothers of 8 - 72-month-old 
children in an SA study had evidence of current or past exposure to 
HBV.[2]
Co-infection with HBV and the human immunodeficiency virus 
(HIV) in sexually active women of reproductive age is of significant 
public health importance because such women are at risk of ongoing 
HBV transmission, both horizontally and perinatally.[3] A fixed-
dose combination (FDC) antiretroviral (ARV) regimen consisting 
of tenofovir (TDF), emtricitabine (FTC) and efavirenz (EFV) is 
currently recommended for all HIV-positive pregnant women 
regardless of their CD4+ cell count.[4] Since TDF and FTC are also 
effective in the treatment of HBV infection, these prevention of 
mother-to-child transmission (PMTCT) guidelines are the first in 
SA to offer simultaneous prevention of HIV and HBV perinatal 
transmission.[5] In women who do not meet the eligibility criteria 
for ongoing treatment, i.e. a CD4+ count of ≤350 cells/µl, the FDC 
regimen is intended to be prophylactic and discontinued 1 week after 
cessation of breastfeeding.[4] The guidelines therefore recommend 
HBV screening prior to discontinuing the ARV regimen to avoid 
maternal HBV reactivation.[4] The potential disadvantage of this 
delayed screening is failure to identify the HBV-exposed neonate and 
protect it at birth against developing chronic HBV infection.
Childhood immunisation programmes, which include HBV 
vaccination from 6 weeks of age, protect the majority of children and 
young adults against chronic hepatitis and liver-related mortality. 
Infants born to HBV/HIV co-infected women are, however, more likely 
to be infected perinatally and are at greater risk of developing chronic 
hepatitis than infants born to HBV mono-infected women.[3] Routine 
antenatal HBV screening is not offered in SA, yet local studies 
reported HBV prevalence rates ranging between 3.2% and 7.4% 
in HIV-infected pregnant women.[3,6] The aim of our study was to 
establish the prevalence of HBV infection and HBV/HIV co-infection 
in pregnant women in KwaZulu-Natal (KZN), to inform antenatal 
HBV screening and childhood immunisation policies in SA.
Methods
Stored (-70°C) plasma specimens were tested for HBV markers in 
a retrospective analysis of pregnant women who participated in an 
HIV sero-incidence study in KZN between March and December 
2009.[7] Consent for ‘storage of plasma intended for use in further 
research’ was obtained from participants at enrolment into the 
original study. The process of participant recruitment, eligibility 
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criteria and HIV testing procedures have 
been described previously.[7] Plasma aliquots 
from 570 stored specimens were selected 
based on an estimated HBV prevalence of 
5.5%.[8] The participants’ ages, HIV status 
and CD4+ counts were extracted from the 
original study database. 
Laboratory analysis
Frozen plasma specimens were thawed and 
tested for hepatitis B surface antigen (HBsAg) 
using an enzyme-linked immunosorbent 
assay (ELISA) from Siemens Healthcare 
Diagnostics (Tarrytown, NY, USA). If 
HBsAg-positive, specimens were further 
tested for hepatitis B e antigen (HBeAg), also 
using an ELISA from Siemens Healthcare 
Diagnostics, and for quantitative HBV 
DNA using the COBAS AmpliPrep/COBAS 
TaqMan HBV Test, version 2.0, from Roche 
Molecular Systems Inc. (Branchburg, NJ, 
USA). HBV infection was characterised by 
a positive HBsAg result and hepatitis B viral 
infectivity by the presence of HBeAg and/or 
HBV DNA quantification.
Specimens with low HBsAg and HBeAg 
index values were not retested for confirmation 
owing to insufficient specimen volumes. 
HBsAg specimens with index values of ≥1 
and ≤50 were further neutralised to confirm 
the presence of HBsAg, and specimens that 
produced technically invalid results were 
excluded from the analysis. HBeAg index 
values of ≥10 were interpreted as positive.
The linear range for HBV DNA 
quantification was 20 - 1.7×108 IU/ml. 
Specimens with an insufficient volume were 
diluted and the final results were calculated 
by multiplication using the dilution factor.
Statistical analysis
Prevalence rates for HBV infection and 
HBV/HIV co-infection were reported as 
point estimates with 95% confidence 
intervals (CIs). Differences in proportions 
were determined by the chi-square test 
(and Fisher’s exact test, where Cochrane’s 
criterion was not fulfilled). Two-tailed 
non-parametric procedures were used to 
compare HBV DNA load between groups. A 
p-value of <0.05 was regarded as significant. 
SAS 9.3 (SAS Institute Inc., Cary, NC, USA) 
was used for statistical analysis.
Ethical considerations
Ethical approval was obtained from the 
University of KwaZulu-Natal Biomedical 
Research Ethics Committee (BE028/12).
Results
Five hundred and seventeen of 570 (90.7%) 
pregnant women (median age 23 years, 
range 16 - 47 years) had their HIV status 
documented; 215 (41.6%) were HIV-positive.
Thirty tested positive for HBsAg, resulting 
in a point prevalence estimate of 5.3% (95% 
CI 3.4 - 7.1). Of these women, 6 were 
HBeAg-positive (20.0%; 95% CI 5.7 - 34.3). 
Twenty-five HBsAg-positive specimens 
(83.3%) had detectable HBV DNA, ranging 
from 20 to >1.7×108 IU/ml with a median 
log10 viral load of 3.0 (interquartile range 
(IQR) 2.3).
Although not statistically significant, more 
HIV-infected women than HIV-uninfected 
women tested HBsAg-positive (p=0.2048) 
(Table 1). Overall, 16 of 509 (3.1%; 95% CI 
1.7 - 4.6) pregnant women with HIV and 
HBsAg results were HBV/HIV co-infected. 
HBeAg positivity was significantly more 
common in HIV-infected than in HIV-
uninfected women (p=0.0185) (Table 1). 
All 16 HBV/HIV co-infected women had a 
detectable HBV DNA load ranging from 45 
to >1.7×108 IU/ml with a median log10 viral 
load of 3.3 (IQR 3.9), which was significantly 
higher than in HIV-uninfected women 
(Table 1).
A CD4+ cell count was available for 76/215 
(35.4%) HIV-positive pregnant women, with 
a median of 328 cells/µl (range 45 - 822 ; IQR 
183). Of these women, 41 (53.9%) had a 
CD4+ count of ≤350 cells/µl and would have 
been eligible for lifelong ARV treatment. 
Four of the 41 women (9.7%) with a CD4+ 
count of ≤350 cells/µl were HBV-co-infected, 
while none of the women with a CD4+ count 
of >350  cells/µl was co-infected (p=0.119 
using Fisher’s exact test, two-tailed).
Discussion
We report an estimated HBV prevalence 
of 5.3% in pregnant women attending 
primary health clinics in KZN. It is highly 
likely that most of the pregnant women in 
our study had missed the childhood EPI 
vaccination. [2] One in 5 (20%) of these HBV-
infected women had active viral replication, 
as indicated by the presence of HBeAg. We 
further report a 7.4% HBsAg prevalence 
in HIV-infected pregnant women in 
KZN, which is higher than the 4.3%, 5.9% 
and 6.2% reported from studies in HIV-
infected pregnant women in North West, 
the Western Cape and Limpopo provinces, 
respectively.[3,6] This regional variation in 
HBV prevalence may be due to various 
cultural and environmental factors that 
modify HBV transmission in diverse ethnic 
groups.[9] The non-significant difference in 
HBV prevalence between HIV-infected and 
uninfected pregnant women demonstrated 
in our study is similar to that reported in 
other SA studies and may be explained by 
early childhood cryptic transmission of HBV 
rather than shared routes of HIV and HBV 
transmission in adulthood.[6]
The 3.1% HBV/HIV co-infection rate in 
our study population is clinically significant 
in a setting with a high HIV burden. HBV/
HIV co-infected pregnant women require 
complex management, since the impact 
on the mother and the infant must be 
considered. The FDC ARV regimen (TDF/
FTC/EFV) currently recommended for all 
HIV-positive pregnant women benefits the 
mother with HBV co-infection and also 
offers protection against HBV infection 
to the exposed neonate by reducing 
the maternal HBV DNA load, which is 
an independent risk factor for perinatal 
transmission.[5,10,11] This strategy provides 
a great advantage over the past zidovudine 
and single-dose nevirapine (NVP) PMTCT 
regimen in which a single postpartum 
dose of TDF and FTC was given.[12] While 
this was intended to protect the mother 
from developing NVP resistance, it offered 
no benefit to the mother or her exposed 
neonate if she was also HBV-infected. The 
use of antenatal ARVs against hepatitis B 
has been shown to be relatively safe and may 
compensate for immunoprophylaxis failure, 
especially in resource-limited settings 
where early access to immunisation is not 
always available. [5,10,13] The new national 
PMTCT guidelines recommend maternal 
HBV screening of all HIV-infected women 
Table 1. Distribution of hepatitis B virus laboratory markers in HIV-infected  
and -uninfected pregnant women
Laboratory markers HIV-infected HIV-uninfected p-value
HBsAg+, n (%) 16/215 (7.4) 14/294* (4.8) 0.2048†
HBeAg+, n (%) 6/16 (37.5) 0/14 (0.0) 0.0185‡
HBV DNA load, median (IQR) 3.3 log10 (3.9) 1.5 log10 (2.1) 0.0058§
HBsAg = hepatitis B surface antigen; HBeAg = hepatitis B e antigen; HBV = hepatitis B virus; + = positive;  
IQR = interquartile range.
*Excludes 8 HBsAg invalid results.
†Chi-squared test.
‡Fisher’s exact test.
§Two-tailed non-parametric test.
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receiving FDC prior to discontinuing the prophylactic ARV regimen 
at cessation of breastfeeding.[4] This strategy protects HBV/HIV 
co-infected women from developing hepatitis flares. However, 
postnatal HBV screening, as opposed to antenatal screening, would 
unfortunately be too late to identify HBV-exposed neonates who 
would have required HBV immunisation at birth.[4,14]
Furthermore, it is highly likely that the 5.3% of neonates in 
our study who were HBV-exposed were not vaccinated at birth as 
recommended, since HBV screening in pregnancy is not routinely 
available and the HBV infection in these women would have gone 
undetected. The higher HBV infectivity demonstrated in HBV/
HIV co-infected pregnant women in our study is consistent with 
other recent studies, and suggests that mother-to-child transmission 
(MTCT) of HBV may be more common in this country than has 
previously been thought.[3,6,15] Perinatal HBV transmission often 
results in an asymptomatic neonatal infection, and 70 - 90% of these 
neonates remain chronically infected if HBV immunoprophylaxis is 
not given at birth.[16] They will subsequently contribute to the reservoir 
of asymptomatic HBV carriers as adults.[16] Inclusion of the HBV 
vaccine into the South African EPI has reduced the childhood HBV 
prevalence, but vaccination initiated at 6 weeks of age is inadequate to 
protect against perinatal HBV transmission.[3,6] Immunoprophylaxis 
failure has been reported despite the suppression of HBV DNA load 
with antenatal ARVs, suggesting that other maternal and obstetric 
factors may influence transmission.[11] Inability to prevent perinatal 
transmission from high-risk HBV/HIV co-infected mothers will 
result in a residual pool of HBV-infected children who will be a 
source of ongoing transmission to others, and this may impede 
current vaccination efforts.
Our failure to investigate occult HBV infections may have meant 
that we underestimated HBV prevalence. The rate of occult HBV 
infection in HIV-infected individuals is estimated to be 33%.[17] 
Testing for occult HBV infection could not be performed in our 
retrospective analysis owing to inadequate specimen volume for 
hepatitis B core antibody testing and confirmatory molecular testing. 
However, the unknown clinical significance of occult HBV infection, 
particularly its role in HBV transmission, together with the high cost 
of HBV molecular screening for an accurate diagnosis, means that it 
is unlikely to be included in a public health policy.[18]
Routine antenatal HBV screening in pregnant women in SA 
will allow for the timeous initiation of infant immunoprophylaxis 
and identification of HBV-exposed neonates who require post-
immunisation serological testing to confirm HBV status. Active and 
passive immunisation given to the neonate within 12 - 24 hours of 
birth (before the development of HBV surface antigenaemia) was 
shown to prevent more than 95% of perinatal transmissions.[5,14] 
However, in a developing country where many women may not 
access antenatal care, initiating the HBV vaccination schedule in 
all infants at birth rather than at 6 weeks could aid in preventing 
perinatal HBV transmission.
Conclusion
We report an estimated 5.3% prevalence of HBV infection and a 
3.1% prevalence of HBV/HIV co-infection in pregnant women 
in this HIV-endemic region. It is highly likely that most women 
of reproductive age who are also HIV-infected have not received 
childhood HBV immunisation. While the current HIV PMTCT 
guidelines provide potent antenatal ARVs with the potential to 
suppress HBV DNA load and decrease vertical HBV transmission 
in high-risk HBV/HIV co-infected women, approximately 4.8% of 
neonates born to HIV-uninfected women are at risk of perinatal 
HBV infection. Routine antenatal serological screening for HBV 
will identify all HBV-exposed neonates and allow active-passive 
HBV immunoprophylaxis to be initiated at birth, thereby reducing 
the risk of vaccine failure. There are no formal guidelines for 
PMTCT of HBV, but antenatal antiviral therapy in combination with 
immunoprophylaxis initiated at birth will decrease the risk of MTCT 
of HBV, as shown in many studies. This strategy may, in turn, reduce 
infant morbidity and mortality related to HBV infection as well as 
decrease the reservoir for ongoing horizontal HBV transmission. 
Our study confirms other SA reports and highlights the need for SA 
childhood immunisation policies to be revisited. Prospective studies 
assessing the impact of the current PMTCT guidelines on MTCT of 
HBV are needed in the future.
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